DELIVERABLES FOR RESEARCH PROGRAM Clause Samples

DELIVERABLES FOR RESEARCH PROGRAM. The Deliverables for the Research Program are defined in Exhibit 1.23 of the Agreement. AZ AND CK CONFIDENTIAL EXHIBIT 5.6.2 SUPPORT DURING THE [*] WILL: - Perform installation of the [*] at [*]. Given prior preparation, by [*], of the required [*] on the [*] at a [*] this effort is estimated to take [*] to complete. - Supply [*] with a [*] and [*] for its own use in the event of [*] during the [*]. - Train [*] on [*]. - Supply [*] with [*] for the [*] as defined in Deliverables Exhibit 1.23. - Prepare [*] as necessary and [*] to [*] with [*]. IN THE EVENT OF [*], WHETHER DURING THE [*] OR [*], [*] WILL: - Expect that [*] will [*] from the [*] and [*] supplied by [*] during the [*] at [*]. - Answer [*] via phone, video conference or email regarding [*] or [*] to [*] of the CHM. - In the event, that the [*] do not result in a [*] at [*], [*] will on a [*], [*] to the [*] and [*] a [*] of the CHM. * Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. Contacts: CYTOKINETICS, INC. ASTRAZENECA (MEDIA ENQUIRES) Robert I. Blum Steve Brown, +44 (0) 207 304 5033 SVP, Finance and Corporate Develo▇▇▇▇▇, ▇▇▇ CF▇ Scott Young, +1.781.839.4589 (650) 624-3000 Kellie Rivest, +1.781.839.4151 BURNS MCCLELLAN, INC. E. Blair Clar▇ (▇▇▇▇▇▇▇▇▇) o▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇n (▇▇▇▇a) (▇▇▇) ▇13-0006 ▇▇▇ ▇▇▇▇▇▇▇TE RELEASE CYTOK▇▇▇▇▇▇▇ ▇▇▇ ▇▇TRAZENECA ANNOUNCE TECHNOLOGY DEVELOPMENT COLLABORATION FOCUSED ON PREDICTIVE TOXICITY ALLIANCE LEVERAGES CYTOMETRIX(TM) CELLULAR PHENOTYPING TECHNOLOGIES SOUTH SAN FRANCISCO, CA AND LONDON, UK, DEC. 18, 2003 - Cytokinetics, Inc., and AstraZeneca Pharmaceuticals announced today that the two companies have entered into an exclusive collaboration to develop automated imaging-based cellular phenotyping and analysis technologies for the in vitro prediction of hepatotoxicity. The companies have agreed to commit internal resources and combine efforts aimed at addressing an important inflection point in the pharmaceutical discovery and development process. Under the terms of the agreement, AstraZeneca will fund technology development activities at Cytokinetics over a two-year research term. The agreement further provides for a milestone payment and annual licensing fees to be paid to Cytokinetics upon the Cytometrix(TM) Hepatotoxicity Module successfully achieving certain agreed upon performance criteria. "Under this collaboration, we have the pot...